BG103362A - Инсулинови с-пептиди - Google Patents

Инсулинови с-пептиди

Info

Publication number
BG103362A
BG103362A BG103362A BG10336299A BG103362A BG 103362 A BG103362 A BG 103362A BG 103362 A BG103362 A BG 103362A BG 10336299 A BG10336299 A BG 10336299A BG 103362 A BG103362 A BG 103362A
Authority
BG
Bulgaria
Prior art keywords
fragment
peptide
atpase activity
sequence
relates
Prior art date
Application number
BG103362A
Other languages
English (en)
Inventor
John Wahren
Bo - Lennart JOHANSSON
Hans Joernvall
Original Assignee
Creative Peptides Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Peptides Sweden Ab filed Critical Creative Peptides Sweden Ab
Publication of BG103362A publication Critical patent/BG103362A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Изобретението се отнася до пептид, който е фрагмент от човешкия инсулинов С-пептид. Пептидът включва последователността ELGGGPGAG или неин фрагмент, или последователността EGSLQ, или неин фрагмент. Той стимулира Na+K+ATPase активност. Изобретението се отнася и до биомиметични органични съединения. Те проявяват активизиране на Na+K+ATPase активности/или клетъчното свързване към бъбречни тубуларниклетки и фибробласти най-малко на нивото, проявеноот посочените по-горе пептиди или техни фрагменти. Посочените пептиди и съединения са приложими в борбата с диабета и диабетните усложнения или за стимулиране на Na+K+ATPase активност.
BG103362A 1996-09-27 1999-04-27 Инсулинови с-пептиди BG103362A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9603533A SE520392C2 (sv) 1996-09-27 1996-09-27 Specifika peptider för behandling av diabetes mellitus
PCT/GB1997/002627 WO1998013384A1 (en) 1996-09-27 1997-09-26 Insulin c-peptides

Publications (1)

Publication Number Publication Date
BG103362A true BG103362A (bg) 2000-05-31

Family

ID=20404052

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103362A BG103362A (bg) 1996-09-27 1999-04-27 Инсулинови с-пептиди

Country Status (24)

Country Link
US (1) US6610649B2 (bg)
EP (1) EP0938503B1 (bg)
JP (1) JP2001500893A (bg)
KR (1) KR20000048643A (bg)
AT (1) ATE347562T1 (bg)
AU (1) AU741901B2 (bg)
BG (1) BG103362A (bg)
BR (1) BR9711573A (bg)
CA (1) CA2266416C (bg)
CZ (1) CZ108599A3 (bg)
DE (1) DE69737065T2 (bg)
DK (1) DK0938503T3 (bg)
ES (1) ES2278394T3 (bg)
HU (1) HUP0000432A3 (bg)
IL (1) IL129143A0 (bg)
IS (1) IS5008A (bg)
NO (1) NO991483L (bg)
NZ (1) NZ335231A (bg)
PL (1) PL332494A1 (bg)
RU (1) RU2206336C2 (bg)
SE (1) SE520392C2 (bg)
SK (1) SK39499A3 (bg)
TR (1) TR199900694T2 (bg)
WO (1) WO1998013384A1 (bg)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0022342D0 (en) * 2000-09-12 2000-10-25 Creative Peptides Sweden Ab Reduction of the electrocardiographic QT interval
DE10055857A1 (de) * 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
CA2511530C (en) * 2003-01-06 2013-07-09 Emisphere Technologies, Inc. Night-time oral insulin therapy
US20050026826A1 (en) * 2003-01-17 2005-02-03 Margarethe Hoenig Feline proinsulin, insulin and constituent peptides
US20050203001A1 (en) * 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
GB0323979D0 (en) 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
US7557081B2 (en) * 2004-05-27 2009-07-07 Essential Skincare, Llc Alpha-1-acid glycoprotein for the treatment of diabetes
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
GB0601950D0 (en) * 2006-01-31 2006-03-15 Creative Peptides Sweden Ab Compositions and methods of treating diabetes
WO2008019368A2 (en) * 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Albumin-insulin fusion proteins
WO2009046881A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of a peptide combination including c-peptide, as a therapeutic agent
GB0723250D0 (en) * 2007-11-28 2008-01-09 Univ Leeds Compositions and methods for reducing macrovascular complications in diabetic patients
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
EP2334338A2 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of c-peptides
US8410049B2 (en) * 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
JP2013533217A (ja) 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Ｐｅｇ化ｃ−ペプチド
CA2827029C (en) 2011-02-11 2019-07-02 The Regents Of The University Of Michigan Tripeptide compositions and methods
WO2013075117A2 (en) 2011-11-17 2013-05-23 John Wahren Pegylated c-peptide
RU2522897C1 (ru) * 2013-04-16 2014-07-20 Закрытое акционерное общество "ФАРМ-ХОЛДИНГ" Твердая кишечнорастворимая лекарственная форма с-пептида проинсулина для перорального применения (варианты) и способ ее получения (варианты)
KR101676542B1 (ko) * 2014-12-30 2016-11-16 건국대학교 산학협력단 프로인슐린의 면역학적 용도
CN104888201B (zh) * 2015-06-29 2018-04-27 齐锦生 用于防治糖尿病及其慢性并发症的肽类药物
JP7438757B2 (ja) 2017-02-06 2024-02-27 バイオテンプト・ベー・フェー 治療用途のためのヒトｃペプチドとヒトエラスチン受容体との相互作用のペプチドモジュレーター

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU166913B (bg) * 1972-05-15 1975-06-28
JPS5210872B2 (bg) * 1973-07-14 1977-03-26
JPS55105653A (en) * 1978-10-02 1980-08-13 Shionogi & Co Ltd Tyrosyl c-peptides
IL66611A0 (en) 1981-08-27 1982-12-31 Lilly Co Eli Pharmaceutical formulations comprising human insulin and human c-peptide
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4581165A (en) 1984-06-14 1986-04-08 Eli Lilly And Company Anti-diabetic compounds
US5104854A (en) 1989-02-01 1992-04-14 Washington University Antiviral peptides
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
US5364757A (en) 1990-05-21 1994-11-15 Administrators Of The Tulane Educational Fund Methods of supporting a diagnosis of systemic lupus erythematosus
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JPH05268982A (ja) 1992-03-27 1993-10-19 Hoechst Japan Ltd 骨形成作用を有する新規な蛋白質およびその製造法
ES2142867T3 (es) 1992-04-13 2000-05-01 Oklahoma Med Res Found Procedimientos y reactivos para el diagnostico de autoanticuerpos.
WO1994025071A1 (en) 1993-05-05 1994-11-10 Keith Rose Polyoxime compounds and their preparation
AT400723B (de) 1993-08-27 1996-03-25 Biomay Prod & Handel Rekombinante alternaria alternata allergene
EP0788512B1 (en) 1994-07-08 1999-03-24 The Trustees Of Dartmouth College Proinsulin peptide compounds for detecting and treating type i diabetes
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
GB9509164D0 (en) 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
BR9708082A (pt) 1996-03-15 1999-07-27 Corixa Corp Compostos e métodos para a imunoterapia e imunodiagnose de câncer de próstata
US6150500A (en) 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase

Also Published As

Publication number Publication date
HUP0000432A3 (en) 2000-10-30
ATE347562T1 (de) 2006-12-15
AU741901B2 (en) 2001-12-13
SE9603533L (sv) 1998-03-28
IL129143A0 (en) 2000-02-17
IS5008A (is) 1999-03-23
ES2278394T3 (es) 2007-08-01
US6610649B2 (en) 2003-08-26
RU2206336C2 (ru) 2003-06-20
NO991483D0 (no) 1999-03-26
NO991483L (no) 1999-05-18
BR9711573A (pt) 2000-01-18
PL332494A1 (en) 1999-09-13
EP0938503B1 (en) 2006-12-06
US20020107175A1 (en) 2002-08-08
NZ335231A (en) 2000-11-24
KR20000048643A (ko) 2000-07-25
DE69737065T2 (de) 2007-06-28
CZ108599A3 (cs) 1999-08-11
CA2266416C (en) 2008-04-29
DE69737065D1 (en) 2007-01-18
SE9603533D0 (sv) 1996-09-27
EP0938503A1 (en) 1999-09-01
WO1998013384A1 (en) 1998-04-02
CA2266416A1 (en) 1998-04-02
HUP0000432A2 (hu) 2000-08-28
JP2001500893A (ja) 2001-01-23
SK39499A3 (en) 1999-10-08
AU4391597A (en) 1998-04-17
TR199900694T2 (xx) 1999-06-21
SE520392C2 (sv) 2003-07-01
DK0938503T3 (da) 2007-04-10

Similar Documents

Publication Publication Date Title
BG103362A (bg) Инсулинови с-пептиди
DE69531889D1 (de) Biologisch aktive Fragmente des Glucagon ähnlichen, insulinotropen Peptides
EP0295645A3 (en) Method for purifying factor viii:c, von willebrand factor and complexes thereof
DE69833667D1 (de) Polynukleotid kodierend für ein polypeptid mit heparanase-aktivität und dessen expression in transduzierten zellen
ATE273996T1 (de) Zusammensetzung zur therapie von diabetes mellitus und fettsucht
ES2073571T3 (es) Aplicacion de nuevos fragmentos de adn como secuencia que codifica un peptido señal para la secrecion de proteinas maduras, mediante levaduras recombinantes, cassettes de expresion, levaduras transformadas y procedimiento correspondiente de preparacion de proteinas.
EP0919242A3 (en) Method for administering acylated insulin
NZ294743A (en) A formulation for administering transdermally a protein or polypeptide such as insulin
PT1100529E (pt) A timosina beta 4 promove a preparacao de feridas
NZ504752A (en) Hydrophobically-modified protein compositions (particularly hedgehog proteins)
DE69841279D1 (de) Verwendung von humanem Parathyroid-hormon
AU3346289A (en) Heparin-binding proteins, DNA coding for them, processes for producing them as well as therapeutic preparations containing them
WO1999064598A3 (de) Neue insulinanaloga mit erhöhter zinkbindung
EP1132402A4 (en) PEPTIDE FRAGMENTS WITH CELL DEATH PREVENTIVE ACTIVITY
AU5508396A (en) Pcna binding substance
WO2003072126A3 (de) Verwendung eines fibroblastenwachstumsfaktor-bindeproteins zur behandlung und diagnose von diabetischen wundheilungsstörungen
ATE301712T1 (de) Z2-19a, ein menschliches homolog von dem protein 2-19
WO1999053064A3 (en) Methods of delivering glp-1
WO1999031229A3 (en) Peptides and nucleic acids derived from eisenia foetida and the use thereof
WO1999030670A3 (en) Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
WO2001032693A3 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
WO2003044159A9 (en) Zinc finger proteins, polynucleotides encoding same and antibodies thereto
AU7043301A (en) A novel polypeptide, a human protein 9 containing a fragment of p5cr specific sequence
WO2001047957A3 (en) Human fgf-10- (kgf-2)-like protein zfgf-10
WO1994015962A3 (en) Derivatized calcitonins